Clinical Trials Logo

Cardiovascular Risk Factors clinical trials

View clinical trials related to Cardiovascular Risk Factors.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06199869 Recruiting - Clinical trials for Cardiovascular Risk Factors

Cardiovascular Patients With no Standard Modifiable Risk Factors

SMuRF-less-ME1
Start date: January 22, 2024
Phase:
Study type: Observational

A growing number of patients develop atherosclerotic cardiovascular disease (ASCVD) despite the absence of standard modifiable risk factors (SMuRF-less). There is scarcity of studies that address this issue in the Middle Eastern population.

NCT ID: NCT05969665 Recruiting - Physical Activity Clinical Trials

Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors

Start date: February 7, 2024
Phase: N/A
Study type: Interventional

The study aims to assess the effect of smart watches and continuous glucose measuring devices on cardiovascular risk factors.

NCT ID: NCT05725096 Recruiting - Clinical trials for Adherence, Medication

Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population

RESPECT2
Start date: June 28, 2023
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.

NCT ID: NCT05658471 Recruiting - Nicotine Dependence Clinical Trials

Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)

SREC22
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

This is a crossover study that will examine use behaviors, chemical exposures, and biological effects of Standardized Research Electronic Cigarette (SREC) compared to usual brand e-cigarette use in natural or synthetic nicotine users.

NCT ID: NCT05441865 Recruiting - Cognitive Change Clinical Trials

Cardiovascular Risk Factors and Cognitive Trajectories

Start date: January 1, 2022
Phase:
Study type: Observational

The cognitive trajectory varies among non-demented older adults. In a 12-year follow-up study, we found approximately 5% participants presented rapid cognitive decline. Cardiovascular diseases increased the risk of cognitive decline. However, the influence of cardiovascular risk factors on cognitive decline remained inconsistent. Besides, the potential mechanism of the cardiovascular risk factors and cognitive function has not been fully investigated. Therefore, the proposed program will include two sub-studies. The first sub-study will use the longitudinal data from the Chinese Longitudinal Healthy Longevity Survey to evaluate the influence of cardiovascular risk factors on the trajectories of cognitive function. The second sub-study will recruit cognitive intact older adults with different levels of cardiovascular risk factors. The association among cardiovascular risk factors, cerebral blood flow, brain functional connectivity and cognitive function will be investigated with structural equation modeling. The findings of the proposed program will provide novel insight on preventing cognitive decline from the angle of maintaining healthy vascular function, and will provide evidence in elucidating the potential neurovascular mechanism between cardiovascular risk factors and cognitive function.

NCT ID: NCT05334888 Recruiting - Clinical trials for Cardiovascular Risk Factors

Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach

XCVD
Start date: August 29, 2022
Phase:
Study type: Observational [Patient Registry]

The XCVD study investigates the influence of sex hormones on the composition of the gut microbiome and the possible emergence of cardiovascular risk factors. It will follow 200 healthy transgender individuals for two years during their hormone replacement therapy (HRT) and analyze them for the possible emergence of cardiovascular risk factors in relation to changes in the gut microbiome, metabolome, and immunome. We would also like to phenotype cardiovascular disease.

NCT ID: NCT05184933 Recruiting - Hypertension Clinical Trials

Sleep and Circadian Mechanisms in Hypertension

Start date: August 4, 2022
Phase: N/A
Study type: Interventional

This study is a mechanistic clinical trial designed to investigate the effects of the circadian system and sleep on non-dipping blood pressure (BP) in people with hypertension (HTN).

NCT ID: NCT05169333 Recruiting - Clinical trials for Cardiovascular Diseases

The Oxford Risk Factors And Non-Invasive Imaging Study

ORFAN
Start date: February 23, 2016
Phase:
Study type: Observational [Patient Registry]

ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.

NCT ID: NCT02917928 Recruiting - Clinical trials for Cardiovascular Risk Factors

The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The investigators hypothesise that carnosine supplementation will improve: 1. glycaemic control 2. cardiovascular risk factors 3. cognitive outcomes in patients with prediabetes and type 2 diabetes, and this will be modulated by reduction in chronic low grade inflammation, oxidative stress and circulating advanced glycation end products levels. 3. Aims To determine the potential of carnosine supplementation for 14 weeks to improve glycaemic control in type 2 diabetes, reduce risk factors for cardiovascular disease and improve cognitive function as well as identify metabolic pathways involved, specifically by: 1. Improving glycaemic control (HBA1c, fasting and 2 hour glucose and glucose area under the curve after oral glucose tolerance test) 2. Reducing cardiovascular risk factors (lipids; arterial (aortic) stiffness; central blood pressure (cBP); endothelial function). 3. Improve cognitive function (global cognitive score formed by a composite of 4 cognitive tests) 4. Decrease the chronic low grade inflammation, oxidative stress, advanced glycation end products, and advanced lipoxidation end products, and increase detoxification of reactive carbonyl species (RCSs).

NCT ID: NCT02628353 Recruiting - Blood Pressure Clinical Trials

Effect of a Specific Phenolic Compound on Blood Pressure

PHENOLPRESS
Start date: December 2015
Phase: Phase 3
Study type: Interventional

The study's main objective is to investigate the effects of acute consumption of a preparation containing 100 mg of a specific phenolic compound (patent pending, P201531587) on systolic BP after ingestion of a high fat meal.